A recent study aimed to explore the relationship between the triglyceride glucose-body mass index (TyG-BMI) and 365-day mortality in critically ill patients with coronary heart disease (CHD). This research, conducted by the Wuxi People’s Hospital Affiliated to Nanjing Medical University, analyzed data from the MIMIC-IV database, categorizing patients into three groups based on their TyG-BMI index: low, medium, and high.
The primary outcome of the study was 365-day mortality, with secondary outcomes including hospital survival, intensive care unit (ICU) survival, and 28-day, 90-day, and 180-day mortality. The study used Kaplan-Meier survival curves to assess outcomes across the three TyG-BMI groups. Additionally, multivariate Cox proportional hazards regression models and restricted cubic spline (RCS) curves were employed to determine the relationship between the TyG-BMI index and mortality.
The study involved 889 critically ill patients with CHD, 600 (67.50%) of whom were male with a mean age of 68.37 years, and 289 (32.50%) were female with a mean age of 73.91 years. The results showed that patients with a medium TyG-BMI index had the best prognostic outcome after 365 days, with a higher survival rate compared to both the low and high TyG-BMI index groups (67.68% vs. 56.08% and 63.51%, respectively; P=0.013). Further analysis revealed that the hazard ratio (HR) for 365-day mortality in the medium TyG-BMI group was 0.71 (95% CI 0.54–0.93, P=0.012), indicating a lower risk of mortality.
RCS analysis revealed an L-shaped relationship between TyG-BMI index and 365-day mortality, suggesting that both low and high TyG-BMI indices were associated with higher mortality compared to the medium index.
In conclusion, the TyG-BMI index is significantly associated with 365-day mortality in patients with critical CHD, highlighting its potential as a prognostic marker for long-term outcomes in this patient population.
Related topics:
Semaglutide and Tirzepatide: A Potential Breakthrough for Type 1 Diabetes Treatment
Sitagliptin Phosphate Reduces Chronic Inflammation in Diabetes by Regulating Macrophage Polarization
Tirzepatide Promises Significant Weight Loss in Non-Diabetic Individuals
